Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain:: Selective involvement of the D2 and not D3 receptor

被引:50
作者
Morisset, S
Pilon, C
Tardivel-Lacombe, J
Weinstein, D
Rostene, W
Betancur, C
Sokoloff, P
Schwartz, JC
Arrang, JM
机构
[1] Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France
[2] Hop St Antoine, F-75571 Paris, France
关键词
D O I
10.1124/jpet.300.2.621
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have explored the role of endogenous dopamine in the control of histaminergic neuron activity in mouse brain regions evaluated by changes in tele-methylhistamine (t-MeHA) levels. In vitro, methamphetamine released [H-3]noradrenaline but failed to release [H-3]histamine from synaptosomes. In vivo, methamphetamine enhanced t-MeHA levels by about 2-fold with ED50 values of similar to1 mg/kg in caudate putamen, nucleus accumbens, cerebral cortex, and hypothalamus. This response selectively involved the D-2 and not the D-3 receptor as indicated by its blockade by haloperidol and by its persistence after administration of nafadotride, a D-3 receptor preferential ligand, or in (-/-) D-3 receptor-deficient mice. The t-MeHA response to methamphetamine was delayed compared with the locomotor-activating effect of this drug, suggesting that it is of compensatory nature. In agreement, ciproxifan, an inverse agonist known to enhance histamine neuron activity, decreased the hyperlocomotion induced by methamphetamine. Repeated methamphetamine administration resulted in the expected sensitization to the hyperlocomotor effect of the drug but did not modify either the ED50 or the E-max regarding t-MeHA levels. However, it resulted in an enhanced basal t-MeHA level (+30-40%), which was sustained for at least 11 days after withdrawal in hypothalamus, striatum, and cerebral cortex and suppressed by haloperidol. Hence, both the acute and chronic administration of methamphetamine enhance histamine neuron activity, presumably in a compensatory manner. Repeated methamphetamine administration also resulted in a modified balance in the opposite influences of dopamine and serotonin on histaminergic neurons as revealed by the enhanced response to haloperidol and abolished response to ketanserin, respectively.
引用
收藏
页码:621 / 628
页数:8
相关论文
共 38 条
[1]   A targeted mutation of the D-3 dopamine receptor gene is associated with hyperactivity in mice [J].
Accili, D ;
Fishburn, CS ;
Drago, J ;
Steiner, H ;
Lachowicz, JE ;
Park, BH ;
Gauda, EB ;
Lee, EJ ;
Cool, MH ;
Sibley, DR ;
Gerfen, CR ;
Westphal, H ;
Fuchs, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1945-1949
[2]   AUTO-REGULATION OF HISTAMINE-RELEASE IN BRAIN BY PRESYNAPTIC H-3-RECEPTORS [J].
ARRANG, JM ;
GARBARG, M ;
SCHWARTZ, JC .
NEUROSCIENCE, 1985, 15 (02) :553-562
[3]   REGULATION OF HISTAMINE-RELEASE IN RAT HYPOTHALAMUS AND HIPPOCAMPUS BY PRESYNAPTIC GALANIN RECEPTORS [J].
ARRANG, JM ;
GULATMARNAY, C ;
DEFONTAINE, N ;
SCHWARTZ, JC .
PEPTIDES, 1991, 12 (05) :1113-1117
[4]   A DETAILED MAPPING OF DOPAMINE D-2 RECEPTORS IN RAT CENTRAL-NERVOUS-SYSTEM BY AUTORADIOGRAPHY WITH [I-125] IODOSULPRIDE [J].
BOUTHENET, ML ;
MARTRES, MP ;
SALES, N ;
SCHWARTZ, JC .
NEUROSCIENCE, 1987, 20 (01) :117-155
[5]   THIOPERAMIDE, THE SELECTIVE HISTAMINE-H-3 RECEPTOR ANTAGONIST, ATTENUATES STIMULANT-INDUCED LOCOMOTOR-ACTIVITY IN THE MOUSE [J].
CLAPHAM, J ;
KILPATRICK, GJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 259 (02) :107-114
[6]   BRAIN-STEM AFFERENTS TO THE TUBEROMAMMILLARY NUCLEUS IN THE RAT-BRAIN WITH SPECIAL REFERENCE TO MONOAMINERGIC INNERVATION [J].
ERICSON, H ;
BLOMQVIST, A ;
KOHLER, C .
JOURNAL OF COMPARATIVE NEUROLOGY, 1989, 281 (02) :169-192
[7]   Serotonin excites tuberomammillary neurons by activation of Na+/Ca2+-exchange [J].
Eriksson, KS ;
Stevens, DR ;
Haas, HL .
NEUROPHARMACOLOGY, 2001, 40 (03) :345-351
[8]   SENSITIVE RADIOIMMUNOASSAYS FOR HISTAMINE AND TELE-METHYLHISTAMINE IN THE BRAIN [J].
GARBARG, M ;
POLLARD, H ;
TUONG, MDT ;
SCHWARTZ, JC ;
GROS, C .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (06) :1724-1730
[9]  
GARBARG M, 1992, J PHARMACOL EXP THER, V263, P304
[10]  
GARBARG M, 1983, METHODS BIOGENIC AMI, P623